中国人群中血清TK1对原发性肝癌诊断价值的meta分析

doi:10.3760/cma.j.issn.1007-1245.2023.05.004

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (5): 606-613.DOI: 10.3760/cma.j.issn.1007-1245.2023.05.004

中国人群中血清TK1对原发性肝癌诊断价值的meta分析

皮爱荣¹ 彭伟²

¹岳阳市中心医院检验科，岳阳　414000；²湖南师范大学附属湘东医院检验科，醴陵　412200

收稿日期:2022-11-05 出版日期:2023-03-01 发布日期:2023-03-28
通讯作者: 皮爱荣，Email：49383478@qq.com

Diagnostic value of serum thymidine kinase 1 in Chinese population with primary liver cancer: a meta-analysis

Pi Airong¹, Peng Wei²

¹Clinical Laboratory, Yueyang Central Hospital, Yueyang 414000, China; ²Clinical Laboratory, Xiangdong Hospital, Hunan Normal University, Liling 412200, China

Received:2022-11-05 Online:2023-03-01 Published:2023-03-28
Contact: Pi Airong, Email: 49383478@qq.com

摘要/Abstract

摘要：

目的　通过meta分析研究中国人群中血清胸苷激酶1（TK1）对原发性肝癌的诊断价值。方法　通过计算机检索数据库中有关中国人群中血清TK1在原发性肝癌诊断方面的相关文献，对文献进行质量评价，通过Stata 17.0对研究结果进行综合评价。文献检索时间从建库至2022年8月31日。结果　共纳入22篇文献，meta分析结果显示TK1对原发性肝癌诊断的灵敏度（SE）=0.73（95%CI 0.67～0.78，P<0.05）、特异度（SP）=0.89（95%CI 0.85～0.92，P<0.05）、阳性似然比（PLR）=6.47（95%CI 4.76～8.80，P<0.05）、阴性似然比（NLR）=0.31（95%CI 0.25～0.37，P<0.05）、诊断比值比（DOR）=21.22（95%CI 13.42～33.55，P<0.05）、综合受试者工作特征曲线下面积（SROC-AUC）=0.88（95%CI 0.85～0.91，P<0.05）。TK1、甲胎蛋白（AFP）、Dickkopf-1（DKK1）联合诊断原发性肝癌的SE=0.88（95%CI 0.85～0.90，P<0.05）、SP=0.91（95%CI 0.89～0.93，P<0.05）、PLR=9.89（95%CI 6.72～14.57，P<0.05）、NLR=0.11（95%CI 0.05～0.23，P<0.05），DOR=94.52（95%CI 35.02～255.09，P<0.05）、AUC=0.97（95%CI 0.63～0.99，P<0.05）。联合诊断的Youden指数为0.79，高于TK1单独诊断时的0.66。结论　中国人群中单独检测血清TK1对原发性肝癌的诊断SE尚好，SP较高，具有一定的诊断价值；TK1、AFP、DKK1联合检测对原发性肝癌具有更高的诊断价值。

关键词:

原发性肝癌, TK1, meta分析

Abstract:

Objective　To evaluate the diagnostic value of serum thymidine kinase 1 (TK1) in Chinese population with primary liver cancer (PLC) by a meta-analysis. Methods　Literatures about serum TK1 for diagnosing Chinese population with PLC were obtained through searching internet databases. The quality of included literatures was evaluated. Meta-analysis was employed by Stata 17.0. The deadline for literature publishing was August 31, 2022. Results　Totally 22 literatures were included. The results of meta-analysis showed that the sensitivity (SE) and specificity (SP) of TK1 for the diagnosis of PLC were 0.73 (95%CI 0.67-0.78, P<0.05) and 0.89 (95%CI 0.85-0.92, P<0.05), the positive likelihood ratio (PLR) was 6.47 (95%CI 4.76-8.80, P<0.05), the negative likelihood ratio (NLR) was 0.31 (95%CI 0.25-0.37, P<0.05), the diagnostic odds ratio (DOR) was 21.22 (95%CI 13.42-33.55, P<0.05), and the area under the summary receiver operating characteristic curve (SROC-AUC) was 0.88 (95%CI 0.85-0.91, P<0.05). The SE of the combination of TK1, alpha-fetoprotein (AFP), and Dickkopf-1 (DKK1) in the diagnosis of PLC was 0.88 (95%CI 0.85-0.90, P<0.05), the SP was 0.91 (95%CI 0.89-0.93, P<0.05), the PLR was 9.89 (95%CI 6.72-14.57, P<0.05), the NLR was 0.11 (95%CI 0.05-0.23, P<0.05), the DOR was 94.52 (95%CI 35.02-255.09, P<0.05), and the AUC was 0.97 (95%CI 0.63-0.99, P<0.05). The Youden index of combined diagnosis was 0.79, which was higher than 0.66 of TK1 alone. Conclusions　The SE of serum TK1 alone as a diagnostic index of PLC in Chinese population is fair, with a high SP, so it has a certain diagnostic value. The diagnostic value of TK1 combined with AFP and DKK1 is higher.

Key words:

Primary liver cancer, Thymidine kinase 1, Meta-analysis

皮爱荣彭伟.

中国人群中血清TK1对原发性肝癌诊断价值的meta分析 [J]. 国际医药卫生导报, 2023, 29(5): 606-613.

Pi Airong, Peng Wei.

Diagnostic value of serum thymidine kinase 1 in Chinese population with primary liver cancer: a meta-analysis [J]. International Medicine and Health Guidance News, 2023, 29(5): 606-613.

参考文献

[1] 姜敏,赵玉军. ATP6V1C1在肝细胞癌中的表达及功能研究[J]. 国际医药卫生导报,2022,28(9):1270-1276. DOI:10.3760/cma.j.issn.1007-1245.2022.09.021.
[2] Gatt ME, Goldschmidt N, Kalichman I, et al. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation[J]. Anticancer Res, 2015, 35(5): 3019-3026.
[3] 欧文,李成杰,任鸿萍,等. 原发性肝癌MRI检查图像特征分析及联合血清AFP、TK1、DKK1的诊断价值研究[J]. 现代生物医学进展,2021,21(9):1777-1780. DOI:10.13241/j.cnki.pmb.2021.09.039.
[4] 胡燕红,顾艳红,王新梅. 血清TK1、VEGF和AFP检测对原发性肝癌诊断及预后评估的价值[J]. 分子诊断与治疗杂志,2020,12(7):901-904. DOI: 10.19930/j.cnki.jmdt.2020. 07.015.
[5] 万敏. AFP、TK1、HSP70表达情况对原发性肝癌的诊断价值分析[J/CD]. 临床医药文献电子杂志,2020,7(54):128-129. DOI:10.16281/j.cnki.jocml.2020.54.091.
[6] 郑笑笑. 血清AFP、TK1、DKK1水平联合检测对原发性肝癌诊断效能的影响[J]. 首都食品与医药,2019,26(24):116-117. DOI:10.3969/j.issn.1005-8257.2019.24.095.
[7] 陈壮荣,黄伟,陈灵芝,等. 甲胎蛋白、胸苷激酶1、Dickkopf相关蛋白1联合检测在原发性肝癌中的诊断价值[J]. 癌症进展,2019,17(17):2059-2061,2065. DOI:10.11877/j.issn.1672-1535.2019.17.17.20.
[8] 季沈杰,龚莉. 血清AFP、CA125、TK1联合检测对原发性肝癌的诊断价值[J]. 热带医学杂志,2018,18(11):1482-1485. DOI:10.3969/j.issn.1672-3619.2018.11.020.
[9] 谢荣章,陈树华. 联合血清AFP、TK1及DKK1水平检测对原发性肝癌诊断价值研究[J]. 国际检验医学杂志,2018,39(8):939-941,946. DOI:10.3969/j.issn.1673-4130.2018. 08.012.
[10] 裴启福,李华. 血清APT、TK1、HSP70水平在诊断原发性肝癌中的临床意义[J]. 标记免疫分析与临床,2017,24(10):1119-1122. DOI:10.11748/bjmy.issn.1006-1703.2017. 10.011.
[11] 李军. 血清AFP、TK1、DKK1联合检测在原发性肝癌诊断中的价值[J]. 基因组学与应用生物学,2017,36(9):3526-3531. DOI:10.13417/j.gab.036.003526.
[12] 王芳,崔舒,王凤梅,等. 血清胸苷激酶1在肝癌中表达升高和BCLC分期相关[J]. 世界华人消化杂志,2017,25(20):1861-1868. DOI:10.11569/wcjd.v25.i20.1861.
[13] 高福磊,黄祥忠. 浅论血清TK1、AFP联合检测在原发性肝癌诊断中的价值[J]. 当代医药论丛,2017,15(14):135-136.
[14] 唐艳萍,谢雨萱,蔡政民,等. 肝癌患者术前血清胸苷激酶1表达水平及其临床意义[J]. 广西医学,2016,38(9):1219-1221. DOI:10.11675/j.issn.0253-4304.2016.09.08.
[15] 李祚品,张平安. 血清AFP、TK1、DKK1联合检测对原发性肝癌的诊断价值[J]. 现代中西医结合杂志,2016,25(1):94-95,98. DOI:10.3969/j.issn.1008-8849.2016.01.036.
[16] 秦继宝,薄维波. 血清AFP、TK1、DKK1联合检测对原发性肝癌的诊断价值[J]. 临床检验杂志,2014,32(7):545-547. DOI:10.13602/j.cnki.jcls.2014.07.19.
[17] 郑小蔚.血清TK1检测在原发性肝癌诊断中的临床意义[J].中国校医,2013,27(12):936-937.
[18] 王强,谢跃文,夏洁. 血清TK1、AFP、CEA联合检测在原发性肝癌诊断中的临床价值[J]. 国际检验医学杂志,2013,34(9):1101-1102. DOI:10.3969/j.issn.1673-4130.2013. 09.019.
[19] 杜江标,崔英,梁新强,等. 多种肿瘤标志物对原发性肝癌的诊断价值[J]. 广西医科大学学报,2020,37(12):2210-2214. DOI:10.16190/j.cnki.45-1211/r.2020.12.019.
[20] 薄维波,李海英,安仲武,等. 血清PIVKA-Ⅱ、TK1和AFP联合检测在肝细胞癌诊断中的价值[J]. 国际检验医学杂志,2021,42(11):1317-1321. DOI:10.3969/j.issn.1673-4130. 2021.11.009.
[21] 李步任,张惠冰,张诗颜. ROC曲线及Logistic回归评价血清AFU,AFP和TK1在原发性肝癌的诊断价值[J]. 现代检验医学杂志,2015,30(6):56-59. DOI:10.3969/j.issn.1671-7414. 2015.06.016.
[22] 冯茜. Logistic回归和ROC曲线综合评价四种指标对原发性肝癌的诊断价值[J]. 标记免疫分析与临床,2016,23(6):641-644,664. DOI:10.11748/bjmy.issn.1006-1703.2016. 06.013.
[23] Tang Y, Li K, Cai Z, et al. HSP90α combined with AFP and TK1 improved the diagnostic value for hepatocellular carcinoma[J]. Biomark Med, 2020, 14(10):869-878. DOI: 10.2217/bmm-2019-0484.
[24] Gong G, Zheng K, Xue S, et al. Serum AFU, GGT and TK1 levels in PHC patients and their correlation with clinicopathology and diagnostic value[J]. Cell Mol Biol (Noisy-le-grand), 2020, 66(5): 111-116.
[25] The Global Cancer Observatory. Liver [EB/OL]. (2020-12) [2022-02-16]. https://gco.iarc.fr/today/data/factsheets/ cancers/11-Liver-fact-sheet.pdf.
[26] 黄创新,李峥嶸. PIVKA-Ⅱ、GP73、AFP-L3在肝细胞癌患者中的表达及诊断价值研究[J]. 医学理论与实践,2022,35(16):2814-2816. DOI:10.19381/j.issn.1001-7585. 2022.16.047.
[27] 杨唯唯,刘铭,游小芳,等. PIVKA-Ⅱ与AFP对原发性肝癌诊断性能的验证及荟萃分析[J]. 标记免疫分析与临床,2020,27(10):1683-1689,1705. DOI:10.11748/bjmy.issn.1006- 1703.2020.10.011.
[28] 刘燕娜,姚明解,郑素军,等. 血清高尔基体蛋白73在慢性肝病患者中的临床应用[J]. 中华肝脏病杂志,2022,30(1):4-8. DOI:10.3760/cma.j.cn501113-20210210-00084.
[29] Welin M, Kosinska U, Mikkelsen NE, et al. Structures of thymidine kinase 1 of human and mycoplasmic origin[J]. Proc Natl Acad Sci U S A, 2004, 101(52):17970-17975. DOI: 10.1073/pnas.0406332102.

中国人群中血清TK1对原发性肝癌诊断价值的meta分析

Diagnostic value of serum thymidine kinase 1 in Chinese population with primary liver cancer: a meta-analysis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics